Gandara DR, Von Pawel J, Sullivan RN, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001).
Boosten maakt lagere dosering olaparib mogelijk
apr 2024 | Borstkanker, Gynaecologische oncologie, Uro-oncologie